Effect of IL-lra on colonocyte eicosanoid release
Author Information
Author(s): G. S. Smith, C. Rieckenberg, W. E. Longo, D. L. Kaminski, J. E. Mazuski, Y. Deshpande, T. A. Miller
Primary Institution: Department of Surgery, Saint Louis University School of Medicine
Hypothesis
Does an interleukin 1 receptor antagonist (IL-lra) alter cellular release of prostanoids and leukotrienes in a transformed colonic cell line (CACO-2) in the presence of proinflammatory stimuli?
Conclusion
The study suggests that IL-lra can selectively influence eicosanoid production in colonocytes and may have a future clinical role in treating inflammatory disorders of the colon.
Supporting Evidence
- IL-lra treatment significantly inhibited PGE2 release in response to LPS and IL-1.
- IL-lra alone increased the basal release of PGE2.
- LTB4 levels were significantly elevated when cells were pretreated with IL-lra before stimulation.
Takeaway
This study looked at how a special protein can change the way certain cells in the colon release substances that cause inflammation. It found that this protein can help control these substances.
Methodology
The study used a transformed colonocyte cell line (CACO-2) and measured the release of prostaglandin E2 and leukotriene B4 after treatment with IL-lra and proinflammatory stimuli.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website